



Item 2.02 Results of Operations and Financial Conditions.

On November 14, 2018, Cleveland BioLabs, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2018. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit

No. Description

99.1 Press Release titled “Cleveland BioLabs Reports Third Quarter 2018 Financial Results and Development Progress”, dated November 14, 2018

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cleveland BioLabs, Inc.

Date: November 14, 2018 By: /s/ YAKOV KOGAN

Name: Yakov Kogan

Title: Chief Executive Officer